iBET is part of “TRANSVAC-DS – Design Study for a European Vaccine Infrastruture”, a new European project aiming to strengthen European vaccine R&D and Development communities by establishing a permanent and sustainable European infrastructure network.
This infrastructure arises from several scientific, technical, regulatory and financial challenges faced when developing vaccine candidates. This combination of skills and technical capacities are unlikely available at a single organisation. Hence, the infrastructure resulting from TRANSVACDS project aims to facilitate access to innovative R&D services, technical training and state-ofthe-art manufacturing facilities, to promote collaborations within the European vaccine development landscape towards the development of safe, effective and affordable vaccines.
TRANSVAC-DS is a follow-up from two previous transnational projects funded by the European Commission – TRANSVAC and TRANSVAC-2. Similar to previous projects, iBET role in TRANSVACDS is to provide expertise in the fields of bioengineering and process/product monitoring and control. In addition, iBET will also co-coordinate TRANSVAC-DS communication, dissemination and exploitation activities. The TRANSVAC-DS project is coordinated by the European Vaccine Initiative (EVI) and funded by
the European Commission (EC), in the context of the Horizon 2020 Framework Programme. The project consortium comprises twenty-five partners, including leading institutions from the European vaccine R&D field. The Kick-Off Meeting was held on 15 June 2020.

See European Vaccine Initiative (EVI) Press Release